Significance of the Higher Molar Dose of Aflibercept 8 mg

Opinion
Video

Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Aflibercept 8 mg was recently approved for treating age-related macular degeneration and diabetic macular edema. Could you discuss the significance of the higher molar dose?

      Newsletter

      Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

      Subscribe Now!
      Recent Videos
      Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
      Modern monitoring strategies remove major barriers to retina care
      (Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      2 experts in this video
      Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
      Related Content
      Scientists work in a lab, looking at microscopes while data is superimposed over the top of the photo. Concept image for clinical trial research and structural functional endpoints in ophthalmology. Image credit: ©metamorworks – stock.adobe.com

      Imaging the ellipsoid zone line could change the global approach to clinical trials

      Hattie Hayes;Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
      June 13th 2025
      Article

      Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

      PHOTON Results and Their Relation to DME Patients in Your Practice

      PHOTON Results and Their Relation to DME Patients in Your Practice

      July 25th 2024
      Podcast

      John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

      The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

      Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

      Lynda Charters
      June 5th 2025
      Article

      Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      July 24th 2024
      Podcast

      John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

      A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

      EU issues CE mark for AI therapy planning assistant from deepeye Medical

      Jordana Joy
      June 2nd 2025
      Article

      The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

      Two business people in suits shake hands in front of a European Union flag. Concept image for Optegra and EssilorLuxottica acquisition, European expansion, expand into new areas of medical technology. Image credit: ©New Africa – stock.adobe.com

      EssilorLuxottica acquires Optegra clinics with support from MidEuropa

      Hattie Hayes
      May 30th 2025
      Article

      The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

      © 2025 MJH Life Sciences

      All rights reserved.